绥美凯推荐的剂量是多少？

It is composed of three ingredients: DTG (DTG) + Abacavir (ABC) + Lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV drug zidovudine (AZT) in 1987, it has brought hope to AIDS patients. Subsequently, more and more drugs have appeared, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating.

In 2016, GSK announced the launch of integrase DTG (Trivic) in China. This therapeutic agent has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. This time, Suimeicai uses DTG, an integrase inhibitor, as the core drug, and a treatment plan with two backbone drugs, abacavir and lamivudine, and made a single-tablet treatment for promotion, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

How should patients use Suimeikai?

This product should be taken under the guidance of a physician with experience in treating HIV infection.

Adults and adolescents (weighing at least 40 kg)

For adults and adolescents, the recommended dose is one tablet once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given as this product is a fixed-dose tablet and the dose cannot be reduced.

This product is a fixed-dose tablet and should not be used in patients who require dose adjustments. If discontinuation or dose adjustment of one of the active ingredients is necessary, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these drugs.

If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

Pediatric Use: The safety and effectiveness of this product in children under 12 years of age have not been established. No data yet.

Use in Geriatric Patients: There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when used in this age group.